Previous 10 | Next 10 |
CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation ...
CAMBRIDGE, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will host a co...
Cue Biopharma (NASDAQ: CUE ) has commenced dosing of CUE-101 into cohort 5 of its ongoing dose escalation Phase 1 monotherapy trial, in patients with human papilloma virus-positive recurrent/metastatic head and neck squamous cell carcinoma. More news on: Cue Biopharma, Inc., Hea...
CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4 Cohort 5 is fully enrolled, with first patient having been dosed on July 20 Additional patients to be enrolled in cohort 4 to further characterize pharmacodynamics and clinical activity i...
- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine - Enhances Cue Biopharma’s ability to engi...
Thinly traded Cue Biopharma (NASDAQ: CUE ) is up 3% premarket on light volume on the heels of updated data from a Phase 1 clinical trial evaluating lead candidate CUE-101 for the second-line treatment of patients with HPV-positive recurrent/metastatic head and neck squamous cel...
Patient enrollment and data generation remain on schedule with 13 patients having received CUE-101 to date and enrollment continues per protocol to identify a recommended Phase 2 dose Dose-proportional increases in drug exposure combined with observations demonstrating pharmacodynam...
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the ...
Cue Biopharma, Inc. (CUE) CEO Dan Passeri Q1 2020 Earnings Conference Call May 19, 2020 4:30 PM ET Company Participants Ashley Robinson - LifeSci Advisors Dan Passeri - President and Chief Executive Officer Anish Suri - Chief Scientific Officer Ken Pienta - Acting Chief Medical...
Image source: The Motley Fool. Cue Biopharma, Inc. (NASDAQ: CUE) Q1 2020 Earnings Call May 19, 2020 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized capital and workforce requirements to be reduced by approximately 25...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® (pembrolizumab) Median overall survival (mOS) of 20.8 months in second...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it will participate in two investor confe...